From the 8th Clinical Trials on Alzheimer’s Disease (CTAD) in Barcelona, Proteome Sciences is pleased to announce that a recently completed study testing its proprietary inhibitors of casein kinase 1 delta (CK1d) reduced the level of tau phosphorylation in a second in vivo model of Alzheimer’s disease (AD) tauopathy. Compounds were given orally for five days and the level of tau phosphorylation in the brain cortex was reduced compared to the control group. These results confirmed and are consistent with the previous in vivo study in a different AD model that revealed reduced tau phosphorylation when the compounds were given daily for 8 weeks.
Commenting on the results of the study, Dr. Ian Pike, Chief Operating Officer at Proteome Sciences said:
“We now have compelling evidence that both acute and chronic dosing of our CK1d inhibitors is reducing levels of phosphorylated tau in the brains of two different models of AD. Surprisingly, the effect of acute dosing on phosphorylated tau was nearly as potent as the chronic administration.
Using our SysQuant global phosphoproteomic workflow we also saw that acute dosing resulted in some early changes in many of the downstream pathways we have previously identified that are affected by tau toxicity in human AD and were responsive to chronic CK1d inhibitor dosing.
The data from the two in-vivo studies provides excellent support for the beneficial effects of our compounds PS 110 and PS 278-05 and their translation to human disease and adds further substance to our partnering discussions.”